Technical Basis of the endTB Observational Study (EN/RU/ES/FR)

endTB Observational Study had sites in 17 countries. In each country, sites enrolled patients on treatment with bedaquiline and delamanid according to National TB Program guidelines, while collecting clinical and bacteriological data on efficacy and safety. Because many of the endTB Observational Study tools were found to be useful for clinicians and programs that were starting to use the new TB drugs and regimens, we made them freely available at the endTB website.

DR-TB Drugs Under the Microscope: 5th edition

This MSF Access Campaign report – now in its fifth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.

We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.

This report was produced with endTB's support.

endTB Interim Analysis Report (EN / ES / RUS)

Bedaquiline- and delamanid- containing regimens achieve excellent interim treatment response without safety concerns: This report presents the results of three different analyses (a safety analysis, a delamanid analysis, and an injectables analysis) to improve the evidence base for using bedaquiline and delamanid in drug-resistant TB regimens. Available in English, Spanish, and Russian.

eLearning modules

​​​​​​The following eLearning units have been developed to provide guidance to physicians caring for MDR-TB patients enrolled in the endTB project.

Patent Opposition Database

The Patent Opposition Database is a site that allows civil society to share resources and learn about the tools needed to oppose the application or granting of unwarranted patents on medicines. The site contains a wealth of information on existing patent oppositions, patent applications, patent office decisions, court cases and other vital documents that will inform users own preparation for filing an opposition by sharing these resources and the experience of others.

Out of Step: TB policies in 29 countries, 3rd Ed. (2017)

Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease: in 2015, 1.8 million people died from it. While there have been substantial and important innovations in the fight against TB, including faster, more accurate diagnostic tests and the first new medicines in nearly 50 years, deadly gaps remain in implementing and providing access to these advances.

Terms of reference: endTB Medical Committee

The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.

It provides advice to any MSF, PIH and IRD projects for individual patient’s management on a case-by-case basis in answer to requests initiated by clinicians from the projects.

For more information, please download the terms of reference.

PIH MSF MSF UNITAID Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo